GPCR logo

GPCR
Structure Therapeutics Inc - ADR

2,163
Mkt Cap
$2.79B
Volume
732,992.00
52W High
$94.90
52W Low
$15.80
PE Ratio
-14.56
GPCR Fundamentals
Price
$39.19
Prev Close
$38.79
Open
$39.20
50D MA
$46.31
Beta
0.89
Avg. Volume
961,776.38
EPS (Annual)
-$2.39
P/B
1.92
Rev/Employee
$0.00
$2,677.55
Loading...
Loading...
News
all
press releases
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
News Placeholder
More News
News Placeholder
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
News Placeholder
Monashee Scales Back Its Bet on Structure Therapeutics
Key PointsMonashee sold 175,000 Structure Therapeutics shares; estimated trade size approximately $11.98 million based on the mean unadjusted close for the quarter...
News Placeholder
Relative Strength Alert For Structure Therapeutics
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
News Placeholder
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
Key PointsHighVista Strategies sold 69,092 shares of Structure Therapeutics in the first quarter; the estimated transaction value was $4.73 million based on quarterly average prices...
News Placeholder
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
News Placeholder
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.
News Placeholder
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.
News Placeholder
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
Key PointsACT Capital Management sold 38,500 shares of Structure Therapeutics in the first quarter; the estimated transaction value was $2.63 million based on Q1 2026 average prices...
News Placeholder
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available